Vertex VX23-670-001

A phase 1/2, randomised, double-blind, placebo-controlled, single-dose and multiple-dose escalation study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of VX-670 in adult patients with myotonic dystrophy type 1.